Brief: Lexeo Therapeutics Announces Progress In FDA Discussions For LX006 In Friedreich Ataxia Cardiomyopathy
07/10/2025 11:09
Oct 7 (Reuters) - Lexeo Therapeutics Inc LXEO.O: LEXEO THERAPEUTICS ANNOUNCES PROGRESS IN FDA DISCUSSIONS FOR ACCELERATED APPROVAL PATHWAY AND POSITIVE INTERIM CLINICAL DATA FOR LX2006 IN FRIEDREICH ATAXIA CARDIOMYOPATHY LEXEO THERAPEUTICS INC - FDA OPEN TO POOLING DATA FOR LX2006 BLA LEXEO THERAPEUTICS INC - PARTICIPANTS ACHIEVE 23% LVMI REDUCTION AT 12 MONTHS LEXEO THERAPEUTICS INC - IMPROVEMENT OBSERVED IN MFARS FOR LX2006 Source text: ID:nGNX3Fgprj Further company coverage: LXEO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease